RE:RE:RE:According to Bloomberg...My somewhat uneducated guess is that the past structure didn't lead itself to having an individual drug product sales lead. Perhaps the new structure not only allows for something like this, but that the CSO Leisure is structuring sales accountbility with a single individual to strategize, create, lead and push sales for each product that comes along.
SPCEO1 wrote: I will believe it when I see it. I have to wonder if they lost or fired the former Trogarzo lead as this is not optimal timing to be hiring this close to th IV Push approval.
scarlet1967 wrote: Hopefully with launch of IV push/IM
Trogarzo's sales also gain some traction.
Check out this job at Theratechnologies Inc.:
https://www.linkedin.com/jobs/view/3260124383 SPCEO1 wrote: So, you already know to be suspicious since it is Bloomberg and the track record of their sales estimates is poor.
Egrifta sales seem to be doing reasonably well. In dollar terms, sales were at an all-time high in August, but that was largely due to price increases as unit sales in August were only the highest since 2020. While the trend in Egrifta sales seems somwhat hopeful, I still am not expecting some blowout to the upside type numbers for Q3. I am just hoping they will be good enough to keep the company from further cutting their 2022 sales guidance.
Trogarzo sales look flattish for the quarter and really for the last two years.
WIth Egrifta likely having close to 95% gross margins and Trogarzo about half that, I am glad Egrifta is the drug doing better.
Also, on the revenue criterion, they will now qualify for that aspect of the second round of the debt deal. If they can get the F8 filed, then the remainder of the convert will be taken care of.